MARKET

RPRX

RPRX

Royalty Pharma plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

44.90
-1.73
-3.71%
After Hours: 44.90 0 0.00% 17:56 06/11 EDT
OPEN
46.48
PREV CLOSE
46.63
HIGH
46.53
LOW
44.46
VOLUME
2.34M
TURNOVER
--
52 WEEK HIGH
56.50
52 WEEK LOW
34.80
MARKET CAP
26.73B
P/E (TTM)
30.15
1D
5D
1M
3M
1Y
5Y
Royalty Pharma Plc (RPRX) EVP, Research & Investments James F. Reddoch Sold $9. ...
GuruFocus News · 3d ago
Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of June:
GlobeNewswire · 6d ago
Constellation (CNST) Surges on Takeover Deal With MorphoSys
Zacks.com · 06/03 17:16
MorphoSys Buys Constellation Pharma in $1.7B Deal. Is Biotech M&A Back?
The deal comes amid a biotech slump, when biotech deal making has been notably slow. The weakness in biotech stocks could lead to an M&A boom, says one analyst.
marketwatch.com · 06/02 14:50
UPDATE 1-Morphosys to acquire Constellation Pharma in $1.7 bln deal
reuters.com · 06/02 14:17
Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys' $1.7 billion acquisition of Constellation Pharmaceuticals (Nasdaq: CNST). This partnership is ex...
GlobeNewswire · 06/02 13:27
MorphoSys to Buy Constellation Pharmaceuticals for $1.7 Billion >MOR CNST
By Colin Kellaher MorphoSys AG Wednesday said it agreed to buy Constellation Pharmaceuticals Inc. for $1.7 billion, or $34 a share. The deal represents a...
marketwatch.com · 06/02 11:53
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) ("Constellation") whe...
ACCESSWIRE · 06/02 11:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RPRX. Analyze the recent business situations of Royalty Pharma plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RPRX stock price target is 52.71 with a high estimate of 56.00 and a low estimate of 50.00.
EPS
Institutional Holdings
Institutions: 241
Institutional Holdings: 247.02M
% Owned: 41.49%
Shares Outstanding: 595.38M
TypeInstitutionsShares
Increased
81
65.44M
New
47
1.30M
Decreased
56
50.42M
Sold Out
34
1.30M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.92%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Chief Executive Officer/Director
Pablo Legorreta
Vice Chairman/Executive Vice President/Director
Christopher Hite
Chief Financial Officer/Executive Vice President
Terrance Coyne
Executive Vice President/General Counsel
George Lloyd
Executive Vice President
James Reddoch
Senior Vice President
Molly Chiaramonte
Senior Vice President
Marshall Urist
Lead Director/Independent Director
Henry Fernandez
Director
M. Germano Giuliani
Director
Rory Riggs
Independent Director
Bonnie Bassler
Independent Director
Errol De Souza
Independent Director
Catherine Engelber
Independent Director
Catherine Engelbert
Independent Director
William Ford
Independent Director
Ted Love
Independent Director
Gregory Norden
Declaration Date
Dividend Per Share
Ex-Div Date
04/15/2021
Dividend USD 0.17
05/19/2021
01/08/2021
Dividend USD 0.17
02/18/2021
10/15/2020
Dividend USD 0.15
11/19/2020
09/02/2020
Dividend USD 0.15
09/14/2020
About RPRX
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.

Webull offers kinds of Royalty Pharma plc stock information, including NASDAQ:RPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RPRX stock methods without spending real money on the virtual paper trading platform.